相关实验视频
Updated: Jan 8, 2026
06:55
Ileectomy-induced Bile Overaccumulation in Mouse Intestine
Published on: August 21, 2017
10.0K
在治疗肥胖症的提尔泽帕提德治疗期间,椎阻塞和肝形成
Bethany Taylor1, Edward Farley-Hills1, Wah Yang2
1Department of Anaesthesia and Intensive Care, Betsi Cadwaladr University Health Board, Bangor, GBR.
Cureus
|December 15, 2025
概括
蒂尔泽帕提德是一种GIP/GLP-1受体激动剂,可能会使先前存在的分泌管疾病复杂化,导致严重的败血症和肝. 临床警对于接受这些疗法的患者至关重要,特别是那些已知有分歧问题的患者.
科学领域:
- 内分泌学 在内分泌学.
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 蒂尔泽帕提德是一种双重依赖葡萄糖的胰岛素托普多 (GIP) / 葡萄糖类-1 (GLP-1) 受体激动剂,广泛用于减肥和血糖控制.
- 胃肠道副作用是已知的提尔泽帕提德治疗的并发症.
- 预先存在的分歧性疾病在恶化之前可能无症状.
研究的目的:
- 报告一例与肝并发症的复杂分泌体炎病例,患者接受了提尔泽帕提德治疗.
- 探索可能的机制,将蒂尔泽帕提德的使用与恶化分支管疾病联系起来.
- 强调需要在患有分歧性疾病的患者中对基于GLP-1的疗法进行临床意识.
主要方法:
- 案例报告的呈现方式.
- 临床评估和患者病史.
- 图像学研究 (例如,CT扫描) 以评估腹部病理.
- 对拟议的病理机制进行文献审查.
主要成果:
- 一名53岁的男性在提尔泽帕提德治疗后经历了严重的败血症和多器官功能障碍.
- 图像检测显示了西格状缩,阻塞性分泌体炎和肝脏.
- 这位患者有先前存在的无症状分歧管疾病.
结论:
- 提尔泽帕提德可能会加剧先前存在的分歧性疾病,可能导致严重的并发症,如败血症和肝.
- 建议的机制包括减少结肠机动性,改变胆汁流和肠道微生物群的变化.
- 需要进行临床警和进一步研究,以确定高风险患者进行例行监测.
相关概念视频
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
859
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
859
01:17Chronic Bowel Disorders: Introduction
732
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
732
01:21Inflammatory Bowel Disease V: Surgical Management
424
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
424
01:17Drugs for Treatment of Diarrhea-Predominant IBS
598
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
598
01:21Drugs for Treatment of Constipation-Predominant IBS
676
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
676
01:30Inflammatory Bowel Disease II: Crohn's Disease
915
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
915